studies | The Memories Project

Tag Archives: studies

April 19, 2026 · 12:49 pm

Study: Alzheimer’s disease progression differences in men, women should be considered when screening

There’s new research supporting previous findings that there are sex-based differences in Alzheimer’s disease progression that should be considered when it comes to screening protocols.

Researchers at Georgia State University (which is just down the street from me) analyzed brain scans of 332 people at different Alzheimer’s stages. While males show earlier gray matter volume loss, their rate of loss tends to plateau, which may result in “earlier onset but slower progression of structural decline.” Conversely, females showed delayed brain atrophy when compared to males, but when the decline did begin, it was at a steeper rate.

The study explores 3 theories that may have an impact on why Alzheimer’s disease evolves differently in men and women: hormonal pathways, APOE-e4 mechanisms, and women’s higher cerebrovascular burden. As I’m a APOE-e4 carrier, it’s concerning that the body of research so far suggests that it contributes to “more severe outcomes in women.” Obviously there’s nothing I can do about genetics, but it’s important to be aware of such factors.

Research will continue in this area to determine if sex-specific screening may support “earlier, more precise interventions.” This is critical because current treatments typically work best in the earlier stages of the disease.

Image created by Google Gemini.

A busy summer for Alzheimer’s research insights

There has been a lot of research on Alzheimer’s and dementia that has been released over the summer. I wrote about the POINTER study, which found that lifestyle interventions can have a positive impact on cognitive health.

A team from the Alzheimer’s Prevention Registry attended the 2025 Alzheimer’s Association International Conference in Toronto in July, where the POINTER findings were discussed among other promising research. The team shared their top takeaways from the conference.

One development that I’m excited about is blood biomarkers, which may facilitate the Alzheimer’s diagnostic process. Blood tests that can be performed on existing medical equipment and reduce the need for expensive and time-consuming PET scans could catch the disease in earlier stages, when current treatments on the market work the best.

Speaking of treatments, some researchers are taking seriously the increased risk of brain bleeds in the latest crop of Alzheimer’s drugs. Scientists are focusing on new technology that could deliver lower doses of drugs that can safely cross the blood-brain barrier. I’ve written about Leqembi, which has seen slow uptake despite being fully approved by the FDA. One of the concerning factors about the drug is the increased risk of brain swelling and bleeding. While the Alzheimer’s community is desperate for new and effective treatments, serious side effects shouldn’t be overlooked.

There’s also new research looking at the role of the immune system and gut microbiome in regards to Alzheimer’s risk. I will definitely be following developments in this area, as I believe that Alzheimer’s and other dementias are not merely brain diseases and require a holistic treatment approach.

Illustration created by Google Gemini.